Clinical trial

Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer

NCT03358017

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-03-05

PhasePHASE2

Study timeline

Study start (actual)2018-03-05Date precision: day

Registry last updated2023-10-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Triple Negative Breast Cancerunresolved

Interventions

ZoledronateDRUG

Atorvastatin 80mgDRUG

Standard neoadjuvant chtDRUG

Sponsors & collaborators

Mario Negri Institute for Pharmacological Researchlead sponsor

Associazione Italiana per la Ricerca sul Cancrocollaborator

Mapped research locations

MilanItaly1 RomaItaly1 BolognaItaly1 PaviaItaly1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03358017 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.